ES2179551T3 - Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn. - Google Patents

Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn.

Info

Publication number
ES2179551T3
ES2179551T3 ES98965783T ES98965783T ES2179551T3 ES 2179551 T3 ES2179551 T3 ES 2179551T3 ES 98965783 T ES98965783 T ES 98965783T ES 98965783 T ES98965783 T ES 98965783T ES 2179551 T3 ES2179551 T3 ES 2179551T3
Authority
ES
Spain
Prior art keywords
neurodermitis
crohn
psoriasis
disease
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98965783T
Other languages
English (en)
Inventor
Rajendra K Joshi
Hans-Peter Strebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen International GmbH
Original Assignee
Fumapharm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm AG filed Critical Fumapharm AG
Application granted granted Critical
Publication of ES2179551T3 publication Critical patent/ES2179551T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Uso de uno o varios alquilfumaratos de hidrógeno de fórmula general **(Fórmula)** donde R es un alquilo C1-5, opcionalmente en mezcla con dialquilfumarato de fórmula **(Fórmula)** y opcionalmente coadyuvantes y vehículos farmacéuticos convencionales para la elaboración de una preparación farmacéutica en forma de microcomprimidos o microgránulos para el tratamiento de la psoriasis, la artritis psoriática, la neurodermitis y la enfermedad de Crohn.
ES98965783T 1998-03-31 1998-12-08 Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn. Expired - Lifetime ES2179551T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19814358A DE19814358C2 (de) 1998-03-31 1998-03-31 Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn

Publications (1)

Publication Number Publication Date
ES2179551T3 true ES2179551T3 (es) 2003-01-16

Family

ID=7863089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98965783T Expired - Lifetime ES2179551T3 (es) 1998-03-31 1998-12-08 Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn.

Country Status (26)

Country Link
US (1) US6277882B1 (es)
EP (1) EP1059920B1 (es)
JP (1) JP3527890B2 (es)
CN (1) CN1150898C (es)
AT (1) ATE219936T1 (es)
AU (1) AU745281B2 (es)
BG (1) BG64744B1 (es)
BR (1) BRPI9815772B8 (es)
CA (1) CA2283915C (es)
CZ (1) CZ291788B6 (es)
DE (2) DE19814358C2 (es)
DK (1) DK1059920T3 (es)
EE (1) EE04702B1 (es)
ES (1) ES2179551T3 (es)
HK (1) HK1035134A1 (es)
HU (1) HU228848B1 (es)
IL (1) IL136835A (es)
NO (1) NO327750B1 (es)
NZ (1) NZ505341A (es)
PL (1) PL191803B1 (es)
PT (1) PT1059920E (es)
RS (1) RS49658B (es)
RU (1) RU2197233C2 (es)
SK (1) SK285187B6 (es)
TR (1) TR200001829T2 (es)
WO (1) WO1999049858A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
JP2004523511A (ja) * 2001-01-12 2004-08-05 フーマファーム アーゲー フマル酸アミド類
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
BRPI0410805A (pt) * 2003-09-09 2006-06-27 Fumapharm Ag uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
DE14172398T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1915387B1 (en) * 2005-07-07 2010-01-20 Aditech Pharma AG Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
HRP20220902T3 (hr) 2007-02-08 2022-10-14 Biogen Ma Inc. Pripravci i njihova upotreba u liječenju multiple skleroze
EP3135282A1 (en) * 2007-02-08 2017-03-01 Biogen MA Inc. Neuroprotection in demyelinating diseases
DK2334378T3 (da) 2008-08-19 2014-07-07 Xenoport Inc Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse
PT2564839T (pt) 2009-01-09 2016-07-14 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
HUE036085T2 (hu) 2011-06-08 2018-06-28 Biogen Ma Inc Nagy tisztaságú és kristályos dimetil-fumarát elõállítására szolgáló eljárás
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CN114146079A (zh) 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
MX2014009511A (es) 2012-02-07 2014-10-24 Xenoport Inc Compuestos de fumarato de morfolinoalquilo, composiciones farmaceuticas y metodos de uso.
KR101449114B1 (ko) * 2012-08-21 2014-10-13 바이오스펙트럼 주식회사 푸마르산을 유효성분으로 포함하는 항염 조성물
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) * 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
US20140179779A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium Substituted Fumarate Derivatives
HUE040044T2 (hu) 2013-03-14 2019-02-28 Alkermes Pharma Ireland Ltd Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
AU2014314231A1 (en) 2013-08-26 2016-03-03 Fwp Ip Aps Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
WO2015042294A1 (en) 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
US20170319548A1 (en) * 2014-09-12 2017-11-09 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
SG11201705124QA (en) 2015-02-08 2017-07-28 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
ES2826825T3 (es) 2015-03-27 2021-05-19 Symbionyx Pharmaceuticals Inc Composiciones y métodos para el tratamiento de la psoriasis
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
CN105496804A (zh) * 2015-12-25 2016-04-20 知识产权全资有限公司 用于处理头发以及治疗头部牛皮藓的配方及其试剂盒和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE3127432A1 (de) * 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) * 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE8714143U1 (de) * 1987-10-23 1988-03-24 Werler Kunststoffwerke GmbH & Co, 4760 Werl Sitz- und/oder Liegemöbel
DE3834794A1 (de) * 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
WO1992012952A1 (en) * 1991-01-18 1992-08-06 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
US5407772A (en) * 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
US5972363A (en) * 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition

Also Published As

Publication number Publication date
RS49658B (sr) 2007-09-21
JP2002509883A (ja) 2002-04-02
NZ505341A (en) 2002-04-26
HU228848B1 (en) 2013-06-28
TR200001829T2 (tr) 2000-11-21
US6277882B1 (en) 2001-08-21
BRPI9815772B1 (pt) 2016-02-10
CZ20003086A3 (cs) 2000-11-15
CZ291788B6 (cs) 2003-05-14
CN1284870A (zh) 2001-02-21
ATE219936T1 (de) 2002-07-15
DE19814358C2 (de) 2002-01-17
BG64744B1 (bg) 2006-02-28
AU2159399A (en) 1999-10-18
BG104566A (en) 2001-01-31
HK1035134A1 (en) 2001-11-16
CA2283915C (en) 2002-12-03
DK1059920T3 (da) 2002-10-14
BRPI9815772B8 (pt) 2021-07-06
NO327750B1 (no) 2009-09-14
AU745281B2 (en) 2002-03-21
EP1059920A1 (de) 2000-12-20
IL136835A (en) 2005-05-17
DE59804704D1 (de) 2002-08-08
CN1150898C (zh) 2004-05-26
PL341240A1 (en) 2001-03-26
RU2197233C2 (ru) 2003-01-27
SK7922000A3 (en) 2001-01-18
EE200000440A (et) 2001-12-17
NO20002872L (no) 2000-06-06
IL136835A0 (en) 2001-06-14
WO1999049858A1 (de) 1999-10-07
EP1059920B1 (de) 2002-07-03
HUP0103234A2 (hu) 2002-01-28
YU32000A (sh) 2002-03-18
HUP0103234A3 (en) 2003-11-28
BRPI9815772A (pt) 2000-11-21
CA2283915A1 (en) 1999-09-30
DE19814358A1 (de) 1999-10-07
NO20002872D0 (no) 2000-06-06
SK285187B6 (sk) 2006-08-03
PT1059920E (pt) 2002-11-29
PL191803B1 (pl) 2006-07-31
JP3527890B2 (ja) 2004-05-17
EE04702B1 (et) 2006-10-16

Similar Documents

Publication Publication Date Title
ES2179551T3 (es) Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn.
MY115662A (en) Novel compounds with analgesic effect
FI972628A (fi) Uudet sulfonamidit
PA8547001A1 (es) Champues con alcohol behenil
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
ATE290015T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
ES2182568T3 (es) Microcomprimidos de acido fumarico.
ATE175669T1 (de) Sulfonylaminopyrimidine, ihre herstellung und verwendung als heilmittel
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
SG55184A1 (en) New imidazopyridines
GB0108591D0 (en) Therapeutic agents
LU91223I2 (fr) Ivabradine et ses dérivés pharmaceutiquement acceptables (procoralan)
ATE203016T1 (de) Cryptophycine
ES2051650A1 (es) Procedimiento para preparar un limpiador de oxigeno activo.
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
TR200400228T4 (tr) Psöryazinin tedavisinde kullanılacak maddeler
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
CO4230037A1 (es) Composicion para aplicacion topica a la piel y/o cabello a base de tensioactivo de fosfato y co-tensioactivo
EP0291269A3 (en) Anti-tumour sulfonyl urea derivatives
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DE69430074T2 (de) Analgetische 4-arylisoindolen
BR9307232A (pt) 4-Estrenos ligados por meio de ponte-19,11 com efic cia gestag-nica
TR199900013T2 (xx) Yeni bile�ikler.
SE9401596D0 (sv) New compounds